Sentences with phrase «efficacy of pembrolizumab»
KEYNOTE - 024 investigated the efficacy of pembrolizumab compared to standard of care with platinum - based chemotherapy in untreated patients with advanced NSCLC and high PD - L1 expression (defined as expression in at least 50 % of tumour cells).
https://www.sciencedaily.com/ Not exact matches
In a phase 1b clinical trial with 21 patients, researchers tested the safety and efficacy of combining the immunotherapy drug pembrolizumab with an oncolytic virus called T - VEC.
«All endpoints of efficacy and tolerability favoured treatment with pembrolizumab, suggesting it should become one standard of care for first line treatment of patients with advanced NSCLC and high PD - L1 expression.
The goals of Cohort B, for which survival data are not yet complete, were, primarily, to prove pembrolizumab's safety and, secondarily, to explore its efficacy as a first - line treatment.
A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO - 2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma
A Randomized, Phase III Trial to Evaluate The Efficacy and Safety of MK - 3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor - Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (yPN +) After Neoadjuvant Chemotherapy
The phase II part of a phase Ib / II study (ClinicalTrials.gov identifier: NCT02263508; MASTERKEY - 265)[24] assessing the safety and efficacy of T - VEC in combination with the PD - 1 — blocking antibody pembrolizumab in previously untreated, unresected stage IIIB / IV melanoma is evaluating confirmed ORR by irRECIST at week 24.
Immune Design entered into clinical collaboration agreements with Merck, known as MSD outside the U.S. and Canada, to evaluate the safety and efficacy of two Immune Design immuno - oncology investigative agents, G100 and LV305, separately combined with KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in Phase 1 trials in patients with non-Hodgkin's lymphoma (NHL) and melanoma, respectively.